ClinicalTrials.Veeva

Menu
C

Clinical Research Trials of Florida, Inc. | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
CTP-543
Risankizumab
ABT-494
Amlitelimab
YKP10811
GB001
Allopurinol
PF-04965842
Dupilumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 23 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling
Asthma
Drug: Placebo
Drug: Rocatinlimab

The goal of this study is to evaluate the efficacy, safety, and tolerability of MK-0616 in adult participants with hypercholesterolemia. The primary...

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: MK-0616
Drug: Placebo

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody re...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Biological: Tdap vaccine

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Tigulixostat
Drug: Placebo

An antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent s...

Enrolling
Clostridoides Difficile Associated Disease
Biological: C. difficile vaccine (previously studied formulation).
Biological: C. difficile vaccine formulation 1.

Trial sponsors

AbbVie logo
Pfizer logo
Merck Sharp & Dohme (MSD) logo
Concert Pharmaceuticals logo
Sanofi logo
A
Amgen logo
G
I
LG Chem logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems